Related Experiment Videos
Virus envelope-based peptide vaccines against virus-induced mammary tumors
A S Dion1, J J Knittel, S T Morneweck
1Center for Molecular Medicine & Immunology, Newark, New Jersey 07103.
Abstract:
Previous studies by us and others established that mammary tumors induced by murine mammary tumor virus (MuMTV) could be prevented to various extents by prior vaccination with MuMTV-containing or subviral component immunogens. In this report, four predicted surface-accessible peptide regions (EP-1 to EP-4) of the major viral envelope glycoprotein (gp52) of C3H-MuMTV were tested as carrier-conjugated vaccines for the protection of Balb/c mice against a live virus challenge. With tumor incidence as an endpoint, vaccination with one of these synthetic peptides (EP-3) resulted in a significant reduction in the frequency of early onset tumors and 67% of the test animals remained tumor-free for the entire observation period (16 months). In contrast, only marginal protection was obtained by immunization with the intact glycoprotein (gp52). Immunologic interference may explain the lower protective efficacy of gp52, as compared to EP-3.
Insights
Vaccinating mice with a synthetic peptide (EP-3) derived from the murine mammary tumor virus (MuMTV) glycoprotein gp52 significantly reduced tumor incidence. This peptide vaccine offered superior protection against MuMTV-induced tumors compared to the intact glycoprotein.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Murine mammary tumor virus (MuMTV) causes mammary tumors in mice.
- Previous research showed vaccination with MuMTV components can prevent tumor development.
- The major viral envelope glycoprotein (gp52) is a key target for immune responses.
Purpose of the Study:
- To evaluate the efficacy of synthetic peptide vaccines derived from MuMTV gp52.
- To assess protection against live MuMTV challenge in Balb/c mice.
- To compare peptide vaccine efficacy with intact gp52 immunization.
Main Methods:
- Four predicted surface-accessible peptide regions (EP-1 to EP-4) of C3H-MuMTV gp52 were synthesized and conjugated.
- Balb/c mice were vaccinated with carrier-conjugated peptides or intact gp52.
- Mice were challenged with live MuMTV, and tumor incidence was monitored over 16 months.
Main Results:
- Vaccination with the synthetic peptide EP-3 significantly reduced early-onset tumor frequency.
- 67% of mice vaccinated with EP-3 remained tumor-free for the entire 16-month observation period.
- Immunization with intact gp52 provided only marginal protection against tumor development.
Conclusions:
- Synthetic peptide vaccines, specifically EP-3, can effectively prevent MuMTV-induced mammary tumors.
- Peptide vaccines targeting specific viral epitopes may offer superior protection compared to intact viral glycoproteins.
- Immunologic interference might explain the reduced efficacy of intact gp52 immunization.